Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has regained compliance with Nasdaq’s minimum bid price rule of $1.00 per American Depositary Share (ADS), following a period of non-compliance that prompted a formal notification in March. The company’s ADSs maintained a closing bid price at or above $1.00 for 19 consecutive business days between August 21 and September 17, according to Nasdaq’s review. Nasdaq confirmed this compliance on September 18, marking the resolution of an earlier violation detected on March 12, when the company’s ADSs failed to meet the $1.00 minimum bid price over 30 consecutive days.
Scinai Regains Nasdaq Compliance After 19-Day Bid Price Hold
Scinai Immunotherapeutics Ltd. returned to full compliance with Nasdaq’s minimum bid price rule after a 19-day period of adherence, following a prior violation in March.
PA
Priya Anand · Equities & Earnings Desk · 21 Sept 2026 · 22:17 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
